Ikena collaborates with leading biopharmaceutical companies to enhance our biomarker-driven discovery and development efforts.
Our discovery research engine utilizes a robust, multidisciplinary approach to elucidate promising targets across pathways in immune cells and in cancer cells, to understand their mechanisms of action, and the biology that drives disease, and to rapidly generate small molecule or biologics targeted oncology and immunometabolism development candidates. We perfect the art of translational research by deliberately connecting the scientific rationale from the lab to the patient benefit in the clinic, moving quickly to a proof of concept (POC) while de-risking the program at every turn.
Our business development team works closely with our research and development groups to thoughtfully identify and evaluate prospective external opportunities that are aligned with our strategic objectives. We actively seek discovery, development and commercialization partners, with the goal of accelerating our ability to advance new oncology therapies to patients.
Are you interested in partnering with Ikena? Please contact us at BD@ikenaoncology.com.